Glenview Capital Management
Overview
Glenview Capital Management is a hedge fund manager that employs a 'Growth at a Reasonable Price' (GARP) strategy, focusing on long/short investments in equity and fixed income securities with a particular emphasis on the healthcare sector.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Lumicell, Inc. | Jul 2023 | Series D | Lead |
| Quanta Dialysis Technologies | Nov 2024 | Series E | Co-investor |
| identifeye HEALTH | Apr 2021 | Series B | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Glenview Capital Management based?
Glenview Capital Management is headquartered in New York City, New York, United States.
When was Glenview Capital Management founded?
Glenview Capital Management was founded in 2000.
How many portfolio companies does Glenview Capital Management have?
Glenview Capital Management has 5 portfolio companies in Caplight's dataset.
What are some companies in Glenview Capital Management's portfolio?
Portfolio companies visible on Caplight include Lumicell, Inc., Quanta Dialysis Technologies, identifeye HEALTH.
What was Glenview Capital Management's most recent investment shown here?
Glenview Capital Management's most recent investment in this portfolio sample was in Quanta Dialysis Technologies in 2024.
What sectors does Glenview Capital Management focus on?
Glenview Capital Management focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, Enterprise Software, AI, Data & Cloud Infrastructure.
What company stages does Glenview Capital Management focus on?
Stage focus information for Glenview Capital Management is not publicly available.
What is Glenview Capital Management's AUM?
Glenview Capital Management's assets under management are estimated between $2.4B and $5.6B.